دورية أكاديمية
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
| العنوان: | Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio. |
|---|---|
| المؤلفون: | Ide D; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan., Fujino T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan., Kobayashi T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan., Egashira A; Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan., Miyashita A; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan., Mizuhara K; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan., Isa R; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.; Department of Hematology, Aiseikai Yamashina Hospital, Kyoto, Japan., Tsukamoto T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan., Mizutani S; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan., Uchiyama H; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.; Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan., Kaneko H; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.; Department of Hematology, Aiseikai Yamashina Hospital, Kyoto, Japan., Uoshima N; Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan., Kawata E; Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.; Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan., Taniwaki M; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Hematology, Aiseikai Yamashina Hospital, Kyoto, Japan., Shimura Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Blood Transfusion, Kyoto Prefectural University of Medicine, Kyoto, Japan., Kuroda J; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. junkuro@koto.kpu-m.ac.jp. |
| المصدر: | International journal of hematology [Int J Hematol] 2024 Jun; Vol. 119 (6), pp. 697-706. Date of Electronic Publication: 2024 Mar 16. |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int J Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2008- : Tokyo : Springer Japan Original Publication: Amsterdam : Elsevier Science Publishers, c1991- |
| مواضيع طبية MeSH: | Lymphoma, Large B-Cell, Diffuse*/therapy , Lymphoma, Large B-Cell, Diffuse*/blood , Lymphoma, Large B-Cell, Diffuse*/diagnosis , Lymphoma, Large B-Cell, Diffuse*/mortality , Monocytes* , Lymphocytes*/pathology, Humans ; Aged ; Male ; Female ; Retrospective Studies ; Middle Aged ; Prognosis ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/therapeutic use ; Rituximab/administration & dosage ; Rituximab/therapeutic use ; Doxorubicin/administration & dosage ; Doxorubicin/therapeutic use ; Recurrence ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Adult ; Vincristine/administration & dosage ; Vincristine/therapeutic use |
| مستخلص: | We conducted a multi-institutional retrospective study in 100 transplant-ineligible (TI) patients with diffuse large B-cell lymphoma (DLBCL) that relapsed or progressed after first-line R-CHOP (or -like) therapy to develop a robust predictive model for TI relapsed/refractory (r/r) DLBCL, which has a heterogeneous but poor prognosis by currently available treatment modalities other than chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies. The median age at relapse or progression was 76 years. The median progression-free survival (PFS) and overall survival (OS) from the first progression were 11.5 months and 21.9 months, respectively. Multivariate analysis identified low lymphocyte-to-monocyte ratio (LMR), elevated high lactate dehydrogenase, and elevated C-reactive protein at progression as independent predictors of OS. A predictive model based on these three factors, here designated as the Kyoto Prognostic Index for r/r DLBCL (KPI-R), successfully stratified their OS and PFS with statistical significance. In addition, event-free survival less than 24 months for R-CHOP and low LMR were identified as significant predictive factors for non-response in any sequence of salvage therapy. We concluded that LMR is a bonafide predictor of treatment response and prognosis in patients with TI r/r DLBCL, and may be helpful in treatment decision-making. (© 2024. Japanese Society of Hematology.) |
| References: | Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53. (PMID: 10.1182/blood.2022015851356535929479027) Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396–407. (PMID: 10.1056/NEJMoa1801445296419666010183) Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551-568.e14. (PMID: 10.1016/j.ccell.2020.03.015322892778459709) Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–90. (PMID: 10.1038/s41591-018-0016-8297130876613387) Pfreundschuh M, Kuhnt E, Trümper L, Österborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22. (PMID: 10.1016/S1470-2045(11)70235-221940214) Camus V, Belot A, Oberic L, Sibon D, Ghesquières H, Thieblemont C, et al. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Adv. 2022;6:6169–79. (PMID: 10.1182/bloodadvances.2022007609357375659772793) Kobayashi T, Kuroda J, Yokota I, Tanba K, Fujino T, Kuwahara S, et al. The Kyoto prognostic index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Cancer J. 2016;6:e383. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351–63. (PMID: 10.1056/NEJMoa211530434904799) Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5. (PMID: 10.1056/NEJM1995120733323057477169) Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403–15. (PMID: 10.1016/S1470-2045(21)00375-234516954) Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20:31–42. (PMID: 10.1016/S1470-2045(18)30864-730518502) Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52. (PMID: 10.1016/S0140-6736(20)31366-032888407) Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:3268–76. (PMID: 10.1182/bloodadvances.2020001900327020977391155) Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7:2872–83. (PMID: 10.1182/bloodadvances.20220090193672451210300297) Prince HM, Imrie K, Michael C, Stkwart AK, Girouard C, Colwill R, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin’s lymphoma: Identification of major prognostic groups. Br J Haematol. 1996;92:880–9. (PMID: 10.1046/j.1365-2141.1996.437976.x8616081) Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8. (PMID: 10.1182/blood-2017-03-769620287748795649550) Bourbon E, Sesques P, Gossez M, Tordo J, Ferrant E, Safar V, et al. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2023;7:744–55. (PMID: 10.1182/bloodadvances.202100656335439292) Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. (PMID: 10.1038/nature01322124909592803035) Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44. (PMID: 10.1038/nature0720518650914) Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86. (PMID: 10.1200/JCO.2006.09.240317242396) Kobayashi T, Yamamoto K, Kagami Y, Machida R, Miyazaki K, Nakamura S, et al. Prognostic value of the Kyoto prognostic index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial. Jpn J Clin Oncol. 2022;52:583–8. (PMID: 10.1093/jjco/hyac039353531869157300) Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066–73. (PMID: 10.1200/JCO.2013.51.5866245504253965261) Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8. (PMID: 10.1038/bmt.2012.24423208313) Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales M-A, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389:148–57. (PMID: 10.1056/NEJMoa230166537272527) Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294–308. (PMID: 10.1016/S0140-6736(22)00662-635717989) Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014;135:362–70. (PMID: 10.1002/ijc.2867724347236) Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110:435–40. (PMID: 10.1038/bjc.2013.78524357796) Wang J, Gao K, Lei W, Dong L, Xuan Q, Feng M, et al. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes. Oncotarget. 2017;8:5414–25. (PMID: 10.18632/oncotarget.1428928036275) Li YL, Gu KS, Pan YY, Jiao Y, Zhai ZM. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. BMC Cancer. 2014;14:341. Katoh D, Ochi Y, Yabushita T, Ono Y, Hiramoto N, Yoshioka S, et al. Peripheral blood lymphocyte-to-monocyte ratio at relapse predicts outcome for patients with relapsed or refractory diffuse large B-cell lymphoma in the rituximab era. Clin Lymphoma Myeloma Leuk. 2017;17:e91–7. (PMID: 10.1016/j.clml.2017.08.09628918104) Lee SF, Luque-Fernandez MA. Prognostic value of lymphocyte-To-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. BMJ Open. 2017;7:e017904. Belotti A, Doni E, Bolis S, Rossini F, Casaroli I, Pezzatti S, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large b-cell lymphoma patients in the rituximab era. Clin Lymphoma Myeloma Leuk. 2015;15:208–13. (PMID: 10.1016/j.clml.2014.10.00125468321) Kumagai S, Tashima M, Fujikawa J, Iwasaki M, Iwamoto Y, Sueki Y, et al. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol. 2014;99:737–42. (PMID: 10.1007/s12185-014-1576-024756873) Goy A, Feldman T, Leslie LA, Skarbnik AP, Wu T, Hansen E, et al. Prognostic value of the absolute lymphocyte to monocyte (ALC/AMC) ratio on overall survival among patients with mantle cell lymphoma. J Clin Oncol. 2017;35:e19030. (PMID: 10.1200/JCO.2017.35.15_suppl.e19030) Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, et al. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Ann Hematol. 2018;97:1009–18. (PMID: 10.1007/s00277-018-3276-y29442162) Lee SF, Ng TY, Spika D. Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis. BMC Cancer. 2019;19:338. Romano A, Parrinello NL, Cerchione C, Consoli ML, Parisi M, Calafiore V, et al. The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. Blood Cancer J. 2017;7:649. Binder M, O’Byrne MM, Maurer MJ, Ansell S, Feldman AL, Cerhan J, et al. Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. Am J Hematol. 2017;92:752–8. (PMID: 10.1002/ajh.2475828383112) Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65. (PMID: 10.1002/path.102711857487) Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61. (PMID: 10.1016/j.immuni.2014.06.010250359534137410) Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18:64. Cioroianu AI, Stinga PI, Sticlaru L, Cioplea MD, Nichita L, Popp C, et al. Tumor microenvironment in diffuse large B-cell lymphoma: role and prognosis. Anal Cell Pathol. 2019;2019:8586354. Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther. 2021;6:10. Maurer MJ, Jakobsen LH, Mwangi R, Schmitz N, Farooq U, Flowers CR, et al. Relapsed/Refractory International Prognostic Index (R/R-IPI): an international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. Am J Hematol. 2021;96(5)599–605. Jiang S, Qin Y, Liu P, Yang J, Yang S, He X, et al. A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients. Asia Pac J Clin Oncol. 2022;18(2):e11–6. (PMID: 10.1111/ajco.1322231264371) |
| فهرسة مساهمة: | Keywords: Diffuse large B-cell lymphoma; Lymphocyte-to-monocyte ratio; Prognostic model; Refractory; Relapse |
| المشرفين على المادة: | 8N3DW7272P (Cyclophosphamide) 0 (R-CHOP protocol) 4F4X42SYQ6 (Rituximab) 80168379AG (Doxorubicin) VB0R961HZT (Prednisone) 5J49Q6B70F (Vincristine) |
| تواريخ الأحداث: | Date Created: 20240316 Date Completed: 20240529 Latest Revision: 20240607 |
| رمز التحديث: | 20240607 |
| DOI: | 10.1007/s12185-024-03750-y |
| PMID: | 38492199 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1865-3774 |
|---|---|
| DOI: | 10.1007/s12185-024-03750-y |